Iretig

Mirabegron, the active ingredient in Iretig, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms such as urinary urgency, frequency, and urge urinary incontinence in adults.

GNH USA supplies Iretig as a licensed, GDP‑compliant international pharmaceutical product, providing reliable supply to hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements across EU and global markets.

Mirabegron is used to manage symptoms of overactive bladder, a condition characterized by involuntary bladder contractions.

- Overactive bladder: improves bladder storage capacity and reduces urgency episodes. - Urinary urgency: lessens the frequency of sudden urges to void. - Urge urinary incontinence: decreases episodes of involuntary leakage.

Adverse reactions reported with Mirabegron include:

Common Side Effects: - Hypertension: elevated blood pressure. - Nasopharyngitis: inflammation of the nasal passages and throat. - Urinary tract infection: bacterial infection of the urinary system. - Headache: mild to moderate head pain. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation.

Serious or Rare Side Effects: - Angioedema: swelling of deep skin layers. - Severe hypertension: markedly high blood pressure. - Urinary retention: difficulty emptying the bladder. - Tachycardia: rapid heart rate. - Allergic reactions: rash, itching, or hives. - Hepatic injury: liver function abnormalities.

When prescribing Mirabegron, clinicians should consider several safety aspects.

- Renal impairment: assess renal function before initiating therapy. - Hepatic impairment: monitor liver function tests during treatment. - Hypertension: check blood pressure regularly and manage elevations. - Drug interactions: review concomitant medications for potential interactions. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Mirabegron may interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors: may increase Mirabegron exposure. - Antimuscarinic agents: additive anticholinergic effects.

Moderate Interactions (Monitor Closely): - Diuretics: may reduce antihypertensive effect. - Nitrates: potential additive blood pressure effects. - Warfarin: monitor INR for anticoagulation changes.